Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Forlong Biotechology inks agreement with Shanghai Henlius Biotech to develop cancer immunotherapy: Shanghai Friday, October 24, 2025, 17:00 Hrs [IST] Forlong Biotechnology, a clin ...

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

Takeda Pharmaceutical Company Limited ( NYSE: TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules October 22, 2025 9:00 AM EDT ...

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell nutrition and Innoventure Dynamic LLC of India announced on October 23, 2025, ...

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across ...